Platelet receptors as therapeutic targets: Past, present and future

Thrombosis and Haemostasis

Volumn 117, Issue 7, 2017, Pages 1249-1257

  Jamasbi, Janina ^a   Ayabe, Keng ^b   Goto, Shinya ^b   Nieswandt, Bernhard ^c   Peter, Karlheinz ^d   Siess, Wolfgang ^a,e  

^a UNIVERSITY OF MUNICH   (Germany)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^e DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Antiplatelet agents; GP Ib ; GP IIb IIIa; GP VI; PAR 1

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANFIBATIDE; ANTITHROMBOCYTIC AGENT; APTAMER; ARC 15105; ATOPAXAR; BMS 986141; CAPLACIZUMAB; CLOPIDOGREL; EGAPTIVON PEGOL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN IB ALPHA; HEPARIN; PLACEBO; PRASUGREL; PROTEINASE ACTIVATED RECEPTOR 1; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; THROMBIN RECEPTOR ANTAGONIST; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOCYTE RECEPTOR; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; VORAPAXAR; PLATELET MEMBRANE GLYCOPROTEIN VI; THROMBIN; THROMBIN RECEPTOR;

ARTICLE; ATHEROSCLEROTIC PLAQUE; BLEEDING DISORDER; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DUAL ANTIPLATELET THERAPY; HIGH RISK PATIENT; HUMAN; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QT PROLONGATION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; METABOLISM; THROMBOCYTE; THROMBOSIS;

BLOOD PLATELETS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET MEMBRANE GLYCOPROTEINS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTOR, PAR-1; THROMBIN; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 85021639236     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-12-0911     Document Type: Article

References (136)

1. Johnston SC, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016; 375: 35-43.
2. Bonaca MP, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800.
3. Metharom P, et al. Current state and novel approaches of antiplatelet therapy. Arterioscler Thromb Vasc Biol 2015; 35: 1327-1338.
4. Firbas C, et al. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther 2010; 8: 1689-1701.
5. Gresele P, Momi S. Inhibitors of the interaction between von Willebrand factor and platelet GPIb/IX/V. Handb Exp Pharmacol 2012; 287-309.
6. Nieswandt B, et al. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J Thromb Haemost 2011; 9 (Suppl 1): 92-104.
7. Nuyttens BP, Thijs T, Deckmyn H, et al. Platelet adhesion to collagen. Thromb Res 2011; 127 (Suppl 2): S26-29.
8. Deckmyn H, et al. Inhibitors of the interactions between collagen and its receptors on platelets. Handb Exp Pharmacol 2012: 311-337.
9. Stegner D, et al. Targeting glycoprotein VI and the immunoreceptor tyrosinebased activation motif signalling pathway. Arterioscler Thromb Vasc Biol 2014; 34: 1615-1620.
10. Jiang P, Jandrot-Perrus M. New advances in treating thrombotic diseases: GPVI as a platelet drug target. Drug Discov Today 2014; 19: 1471-1475.
11. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006; 99: 1293-1304.
12. French SL, et al. Approval of the first protease-activated receptor antagonist: Rationale, development, significance, and considerations of a novel anti-platelet agent. Blood Rev 2015; 29: 179-189.
13. Tantry US, et al. Vorapaxar in the secondary prevention of atherothrombosis. Expert Rev Cardiovasc Ther 2015; 13: 1293-1305.
14. Cattaneo M. P2Y12 receptors: Structure and function. J Thromb Haemost 2015; 13 (Suppl 1): S10-16.
15. Bernlochner I, Sibbing D. Thienopyridines and other ADP-receptor antagonists. Handb Exp Pharmacol 2012: 165-198.
16. Massberg S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-896.
17. Li M, et al. Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model. Atherosclerosis 2007; 194: 348-356.
18. Heim C, et al. Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo. Heart Vessels 2016; 31: 783-794.
19. Ungerer M, et al. The GPVI-Fc fusion protein revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times. PLoS One 2013; 8: e71193.
20. Bultmann A, et al. Impact of glycoprotein VI and platelet adhesion on atherosclerosis--a possible role of fibronectin. J Mol Cell Cardiol 2010; 49: 532-542.
21. Schulz C, et al. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Basic Res Cardiol 2008; 103: 356-367.
22. Gawaz M. Platelets in the onset of atherosclerosis. Blood Cells Mol Dis 2006; 36: 206-210.
23. Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost 2011; 106: 827-838.
24. Ranke C, Hecker H, Creutzig A, et al. Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation 1993; 87: 1873-1879.
25. Kwon SU, et al. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke 2011; 42: 2883-2890.
26. Kodama M, et al. Antiplatelet drugs attenuate progression of carotid intimamedia thickness in subjects with type 2 diabetes. Thromb Res 2000; 97: 239-245.
27. Ridker PM, et al. The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: Clinical evidence from the physicians’ health study. Am Heart J 1991; 122: 1588-1592.
28. Kim BJ, et al. The effect of cilostazol on carotid intima-media thickness progression in patients with symptomatic intracranial atherosclerotic stenosis. J Stroke Cerebrovasc Dis 2014; 23: 1164-1170.
29. Katakami N, et al. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: Principal results of the diabetic atherosclerosis prevention by cilostazol (DAPC) study: A randomized trial. Circulation 2010; 121: 2584-2591.
30. Kawamura Y, et al. Imaging of structural changes in endothelial cells and thrombus formation at the site of FeCl(3)-induced injuries in mice cremasteric arteries. J Atheroscler Thromb 2009; 16: 807-814.
31. Furlan M. Von Willebrand factor: Molecular size and functional activity. Ann Hematol 1996; 72: 341-348.
32. De Meyer SF, et al. Von Willebrand factor to the rescue. Blood 2009; 113: 5049-5057.
33. Federici AB. The factor VIII/von Willebrand factor complex: Basic and clinical issues. Haematologica 2003; 88: EREP02.
34. Marx I, et al. Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood 2008; 112: 603-609.
35. Goto S, et al. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J Clin Invest 1998; 101: 479-486.
36. Siedlecki CA, et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88: 2939-2950.
37. Colace TV, Diamond SL. Direct observation of von Willebrand factor elongation and fibre formation on collagen during acute whole blood exposure to pathological flow. Arterioscler Thromb Vasc Biol 2013; 33: 105-113.
38. Goto S, et al. Characterization of the unique mechanism mediating the sheardependent binding of soluble von Willebrand factor to platelets. J Biol Chem 1995; 270: 23352-23361.
39. Weiss HJ. Abnormalities of factor VIII and platelet aggregation--use of ristocetin in diagnosing the von Willebrand syndrome. Blood 1975; 45: 403-412.
40. Goto S, et al. Platelets: Small in size but essential in the regulation of vascular homeostasis-translation from basic science to clinical medicine. Circ J 2015; 79: 1871-1881.
41. Broos K, et al. Platelets at work in primary hemostasis. Blood Rev 2011; 25: 155-167.
42. Michelson AD, et al. The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible. Blood 1994; 83: 3562-3573.
43. Dumas JJ, et al. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J Biol Chem 2004; 279: 23327-23334.
44. Shiozaki S, Takagi S, Goto S. Prediction of molecular interaction between platelet glycoprotein Ibalpha and von Willebrand factor using molecular dynamics simulations. J Ather Thromb 2016; 23: 455-464.
45. Ruggeri ZM, et al. Activation-independent platelet adhesion and aggregation under elevated shear stress. Blood 2006; 108: 1903-1910.
46. De Marco L, et al. Von Willebrand factor interaction with the glycoprotein IIb/ IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest 1986; 77: 1272-1277.
47. Jackson SP. Arterial thrombosis--insidious, unpredictable and deadly. Nat Med 2011; 17: 1423-1436.
48. Goto S, et al. Abciximab not RGD peptide inhibits von Willebrand factor-dependent platelet activation under shear. Lancet 1999; 353: 809.
49. Boeckelmann D, et al. Patients with Bernard-Soulier syndrome and different severity of the bleeding phenotype. Blood Cells Mol Dis 2017; Epub ahead of print.
50. Lipowsky HH. Microvascular rheology and hemodynamics. Microcirculation 2005; 12: 5-15.
51. Schneppenheim R, Budde U. von Willebrand factor and ADAMTS13 balancing primary haemostasis. Hamostaseologie 2011; 31: 275-280.
52. Kleinschnitz C, et al. Targeting platelets in acute experimental stroke: Impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007; 115: 2323-2330.
53. Kageyama S, et al. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur J Pharmacol 2002; 443: 143-149.
54. Kageyama S, et al. Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res 2001; 101: 395-404.
55. Fontayne A, et al. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost 2008; 100: 670-677.
56. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
57. Peyvandi F, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 2016; 374: 511-522.
58. Clinicaltrials.Gov. 2016; Available from: https://clinicaltrials.gov/ct2/show/NCT02553317.
59. Jilma-Stohlawetz P, et al. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2b von Willebrand disease. Thromb Haemost 2012; 108: 284-290.
60. Bae ON. Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an anti-vWF aptamer, against thrombotic risk. Arch Pharm Res 2012; 35: 1693-1699.
61. Jilma-Stohlawetz P, et al. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost 2011; 105: 545-552.
62. Arzamendi D, et al. An anti-von Willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis. Clin Appl Thromb Hemost 2011; 17: E70-78.
63. Siller-Matula JM, et al. ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. Arterioscler Thromb Vasc Biol 2012; 32: 902-909.
64. Lei X, et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost 2014; 111: 279-289.
65. Li TT, et al. A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury. Br J Pharmacol 2015; 172: 3904-3916.
66. Hou Y LB, et al. The first in vitro and in vivo assessment of anfibatide, a novel glycoprotein Ib antagonist, in mice and in a phase I human clinical trial Blood 2013; 122: 577.
67. Xu XR, et al. Platelets and platelet adhesion molecules: Novel mechanisms of thrombosis and anti-thrombotic therapies. Thromb J 2016; 14: 29.
68. ClinicalTrials.gov. Anfibatide phase Ib-IIa clinical trial. 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT01585259. Accessed December 3, 2016.
69. Andrews RK, et al. Targeting GPVI as a novel antithrombotic strategy. J Blood Med 2014; 5: 59-68.
70. Nieswandt B, et al. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med 2001; 193: 459-469.
71. Li H, et al. The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats. Arterioscler Thromb Vasc Biol 2007; 27: 1199-1205.
72. Ohlmann P, et al. Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression. J Thromb Haemost 2008; 6: 1003-1011.
73. Grüner S, et al. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood 2005; 105: 1492-1499.
74. Arthur JF, et al. Platelet glycoprotein VI-related clinical defects. Br J Haematol 2007; 139: 363-372.
75. Penz S, et al. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. Faseb J 2005; 19: 898-909.
76. Reininger AJ, et al. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J Am Coll Cardiol 2010; 55: 1147-1158.
77. Kuijpers MJ, et al. Complementary roles of glycoprotein VI and alpha2beta1 integrin in collagen-induced thrombus formation in flowing whole blood ex vivo. Faseb J 2003; 17: 685-687.
78. Auger JM, et al. Adhesion of human and mouse platelets to collagen under shear: A unifying model. Faseb J 2005; 19: 825-827.
79. Grüner S, et al. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy. Circulation 2004; 110: 2946-2951.
80. Herr AB, Farndale RW. Structural insights into the interactions between platelet receptors and fibrillar collagen. J Biol Chem 2009; 284: 19781-19785.
81. Zahid M, et al. The future of glycoprotein VI as an antithrombotic target. J Thromb Haemost 2012; 10: 2418-2427.
82. Goto S, et al. Involvement of glycoprotein VI in platelet thrombus formation on both collagen and von Willebrand factor surfaces under flow conditions. Circulation 2002; 106: 266-272.
83. Schonberger T, et al. The dimeric platelet collagen receptor GPVI-Fc reduces platelet adhesion to activated endothelium and preserves myocardial function after transient ischemia in mice. Am J Physiol Cell Physiol 2012; 303: C757-766.
84. Inoue O, et al. Laminin stimulates spreading of platelets through integrin alpha6beta1-dependent activation of GPVI. Blood 2006; 107: 1405-1412.
85. Mammadova-Bach E, et al. Platelet glycoprotein VI binds to polymerized fibrin and promotes thrombin generation. Blood 2015; 126: 683-691.
86. Alshehri OM, et al. Fibrin activates GPVI in human and mouse platelets. Blood 2015; 126: 1601-1608.
87. Katsuda S, Kaji T. Atherosclerosis and extracellular matrix. J Atheroscler Thromb 2003; 10: 267-274.
88. Massberg S, et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. Faseb J 2004; 18: 397-399.
89. Ungerer M, et al. Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 2011; 123: 1891-1899.
90. Jamasbi J, et al. Differential inhibition of human atherosclerotic plaque-induced platelet activation by dimeric GPVI-Fc and anti-GPVI antibodies: Functional and imaging studies. J Am Coll Cardiol 2015; 65: 2404-2415.
91. Walker A, et al. Single domain antibodies against the collagen signalling receptor glycoprotein VI are inhibitors of collagen induced thrombus formation. Platelets 2009; 20: 268-276.
92. Muzard J, et al. Design and humanization of a murine ScFv that blocks human platelet glycoprotein VI in vitro. FEBS J2009; 276: 4207-4222.
93. Kleiman NS, Kolandaivelu K. Expanding the roster: Developing new inhibitors of intravascular thrombosis. J Am Coll Cardiol 2015; 65: 2416-2419.
94. Moreland LW, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-147.
95. Franklin CM. Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis. Semin Arthritis Rheum 1999; 29: 172-181.
96. Jamasbi J, et al. Cross-linking GPVI-Fc by anti-Fc antibodies potentiates its inhibition of atherosclerotic plaque-and collagen-induced platelet activation. J Am Coll Cardiol Basic Translat Sci 2016; 1: 131-142.
97. Armstrong PC, Peter K. GpIIb/IIIa inhibitors: From bench to bedside and back to bench again. Thromb Haemost 2012; 107: 808-814.
98. Bassler N, et al. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists. Arterioscler Thromb Vasc Biol 2007; 27: e9-15.
99. Estevez B, et al. Targeting integrin and integrin signalling in treating thrombosis. Arterioscler Thromb Vasc Biol 2015; 35: 24-29.
100. Schneider DJ. Anti-platelet therapy: Glycoprotein IIb-IIIa antagonists. Br J Clin Pharmacol 2011; 72: 672-682.
101. Bledzka K, et al. Integrin alphaIIbbeta3: From discovery to efficacious therapeutic target. Circ Res 2013; 112: 1189-1200.
102. Nakagawa Y, et al. Efficacy of abciximab for patients undergoing balloon angioplasty: Data from japanese evaluation of c7e3 Fab for elective and primary PCI organization in randomized trial (JEPPORT). Circ J 2009; 73: 145-151.
103. Cox D. Oral gpIIb/IIIa antagonists: What went wrong? Curr Pharm Des 2004; 10: 1587-1596.
104. Hohmann JD, et al. Delayed targeting of CD39 to activated platelet gpIIb/IIIa via a single-chain antibody: Breaking the link between antithrombotic potency and bleeding? Blood 2013; 121: 3067-3075.
105. Wang X, et al. Towards effective and safe thrombolysis and thromboprophylaxis: Preclinical testing of a novel antibody-targeted recombinant plasminogen activator directed against activated platelets. Circ Res 2014; 114: 1083-1093.
106. Li J, et al. RUC-4: A novel alphaIIbbeta3 antagonist for prehospital therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 2014; 34: 2321-2329.
107. Gong H, et al. G protein subunit Galpha13 binds to integrin alphaIIbbeta3 and mediates integrin „outside-in“signalling. Science 2010; 327: 340-343.
108. Shen B, et al. A directional switch of integrin signalling and a new anti-thrombotic strategy. Nature 2013; 503: 131-135.
109. Moschonas IC, et al. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives. Int J Cardiol 2015; 185: 9-18.
110. Tricoci P, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366: 20-33.
111. Tello-Montoliu A, et al. Antiplatelet therapy: Thrombin receptor antagonists. Br J Clin Pharmacol 2011; 72: 658-671.
112. Muller KA, et al. Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD. Thromb Haemost 2015; 114: 498-518.
113. Goto S, et al. Double-blind, placebo-controlled phase II studies of the proteaseactivated receptor 1 antagonist E5555 (atopaxar) in japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 2010; 31: 2601-2613.
114. Wiviott SD, et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: The lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial. Circulation 2011; 123: 1854-1863.
115. Becker RC, et al. Safety and tolerability of SCH530348 in patients undergoing non-urgent percutaneous coronary intervention: A randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373: 919-928.
116. Goto S, et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 2010; 17: 156-164.
117. Morrow DA, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012; 366: 1404-1413.
118. ClinicalTrials.gov. Safety and efficacy study of a protease activated receptor-4 antagonist being tested to reduce the chances of having additional strokes or „mini strokes“. 2016. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02671461?term=par4&rank=4. Accessed December 6, 2016.
119. Goto S, et al. Functional significance of adenosine 5’-diphosphate receptor (P2Y12) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate. Circulation 2002; 105: 2531-2536.
120. Penz SM, et al. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Thromb Haemost 2007; 97: 435-443.
121. Wiviott SD, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITONTIMI 38 trial: A subanalysis of a randomised trial. Lancet 2008; 371: 1353-1363.
122. Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Caprie steering committee. Lancet 1996; 348: 1329-1339.
123. Jackson SP, Schoenwaelder SM. Antiplatelet therapy: In search of the’magic bullet’. Nat Rev Drug Discov 2003; 2: 775-789.
124. Hollopeter G, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207.
125. Savi P, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
126. Goto S, Tomiya A. High on-treatment platelet reactivity (HPR): What does it mean, and does it matter? Thromb Haemost 2013; 109: 177-178.
127. Mega JL, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
128. Mega JL, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009; 119: 2553-2560.
129. Armstrong D, et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther 2014; 19: 209-219.
130. Iyu D, et al. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist. Arterioscler Thromb Vasc Biol 2011; 31: 416-422.
131. Levine GN, et al. Expert consensus document: World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCI. Nat Rev Cardiol 2014; 11: 597-606.
132. Shiraga M, et al. Impaired platelet function in a patient with P2Y12 deficiency caused by a mutation in the translation initiation codon. J Thromb Haemost 2005; 3: 2315-2323.
133. Eikelboom JW, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782.
134. Wiviott SD, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
135. Saito S, et al. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in japanese patients with acute coronary syndrome: The PRASFITACS study. Circ J 2014; 78: 1684-1692.
136. Goto S, et al. Ticagrelor vs. Clopidogrel in japanese, korean and taiwanese patients with acute coronary syndrome--randomized, double-blind, phase III PHILO study. Circ J 2015; 79: 2452-2460.